Methods of treating or preventing neurological diseases

Abstract

The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom.

1 . A method for improving motor function or delaying disease progression in a subject suffering from an inflammatory neurological disease, the method comprising administering to the subject a population of cells enriched for STRO-1 +  multipotential cells. 
     
     
         2 . The method of  claim 1 , wherein the inflammatory neurological disease is associated with or caused by a T cell response to an inflammatory stimulus. 
     
     
         3 . The method of  claim 1  comprising administering a population of cells enriched for STRO-1 bright  multipotential cells. 
     
     
         4 . The method of  claim 1 , wherein the inflammatory neurological disease is selected from the group consisting of multiple sclerosis, systemic lupus erythematosus, Guillain-Barre syndrome, Lambert-Eaton myasthenic syndrome, myasthenia gravis, transverse myelitis, leukodystrophy and progressive multifocal leukoencephalopathy. 
     
     
         5 . The method of  claim 1 , wherein the disease is systemic lupus erythematosus or multiple sclerosis. 
     
     
         6 - 7 . (canceled) 
     
     
         8 . The method of  claim 1 , wherein the population enriched for STRO-1 +  multipotential cells is administered systemically. 
     
     
         9 . (canceled) 
     
     
         10 . The method of  claim 1 , comprising:
 (i) administering an amount of the population enriched for STRO-1 +  multipotential cells effective to increase the number of regulatory T (Treg) cells in the subject and/or at the site of pathogenesis of the disease;   (ii) administering between 2×10 6  to 8×10 6  STRO-1 +  multipotential cells per kg;   (iii) administering between 3×10 6  to 6×10 6  STRO-1 +  multipotential cells per kg; or   (iv) administering a low dose of STRO-1 +  multipotential cells, wherein the low dose of STRO-1 +  multipotential cells comprises between 0.1×10 6  and 3×10 6  STRO-1 +  multipotential cells per kg or comprises about 3×10 6  STRO-1 +  multipotential cells per kg.   
     
     
         11 - 15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein the population enriched for STRO-1 +  multipotential cells are administered once weekly or less often or are administered once every four weeks or less often. 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the population enriched for STRO-1 +  multipotential cells are genetically-engineered to express a molecule to block stimulation of T cells and/or the soluble factors are from such genetically-modified cells or wherein the population enriched for STRO-1 +  multipotential cells are administered with a compound to block stimulation of T cells. 
     
     
         19 . (canceled) 
     
     
         20 . The method of  claim 1 , wherein the population enriched for STRO-1 +  multipotential cells are autogeneic or allogeneic. 
     
     
         21 . The method of  claim 1 , wherein the population enriched for STRO-1 +  multipotential cells have been culture expanded prior to administration. 
     
     
         22 . A method for preventing an immune response in response to an antigen, the method comprising administering to the subject a population of cells enriched for STRO-1 +  multipotential cells. 
     
     
         23 . The method of  claim 22 , wherein the immune response is a T cell-mediated immune response. 
     
     
         24 . (canceled) 
     
     
         25 . The method of  claim 22 , wherein the T cell-mediated immune response is suppressed in response to a specific antigen and a T cell-mediated immune response in response to another antigen is not suppressed. 
     
     
         26 . The method of  claim 22 , wherein the subject has previously raised an immune response to the antigen and the population suppresses a further immune response to the antigen. 
     
     
         27 . The method of  claim 26 , comprising administering the population after the subject raises an immune response to the antigen to thereby prevent a further immune response to the antigen. 
     
     
         28 . The method of  claim 22 , wherein the immune response is suppressed for at least about 24 days following administration of the population of cells enriched for STRO-1 +  multipotential cells. 
     
     
         29 . A method for inducing tolerance to an antigen in a subject, the method comprising administering to the subject a population of cells enriched for STRO-1 +  multipotential cells. 
     
     
         30 . The method of  claim 22 , wherein the antigen is one against which an inflammatory response is raised. 
     
     
         31 . The method of  claim 30 , wherein the inflammatory response is causative of an inflammatory neurological disease. 
     
     
         32 . The method of  claim 1 , wherein the population of cells enriched for STRO-1 +  multipotential cells is administered with a compound that treats or prevents an inflammatory neurological disease. 
     
     
         33 - 35 . (canceled)